+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

NovoCure Ltd (NVCR) - Product Pipeline Analysis, 2020 Update

  • ID: 5240169
  • Company Profile
  • January 2021
  • 67 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Advanz Pharma Corp Ltd
  • Flowonix Medical Inc
  • Hologic Inc
  • MagForce AG
  • MDxHealth SA
  • Monteris Medical Inc
  • MORE
NovoCure Ltd (NovoCure) develops and commercializes novel delivery systems for the treatment of cancers of brain, abdomen, and torso. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies for disrupting the division solid tumor cancer cells. The company markets TTF-based delivery systems: NovoTTF-100L for the treatment of malignant pleural mesothelioma; and Optune for the treatment of glioblastoma. Both of its marketed products are indicated in combination with standard chemotherapies. NovoCure is also advancing product development and clinical programs intended to improve the survival of patients with brain metastases, pancreatic cancer, ovarian cancer, liver cancer, gastric cancer, and non-small cell lung cancer. It has subsidiaries in Europe, the Middle East, Asia, and North America. NovoCure is headquartered in Saint Helier, Jersey, the UK.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company NovoCure Ltd
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Advanz Pharma Corp Ltd
  • Flowonix Medical Inc
  • Hologic Inc
  • MagForce AG
  • MDxHealth SA
  • Monteris Medical Inc
  • MORE
NovoCure Ltd Company Overview
  • NovoCure Ltd Company Snapshot
  • NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • NovoCure Ltd - Pipeline Analysis Overview
  • Business Description
  • NovoCure Ltd - Key Facts
  • NovoCure Ltd - Major Products and Services
  • NovoCure Ltd Pipeline Products by Development Stage
  • NovoCure Ltd Ongoing Clinical Trials by Trial Status
NovoCure Ltd Pipeline Products Overview
  • MAXPOINT Treatment Planning Software
  • MAXPOINT Treatment Planning Software Product Overview
  • NovoTTF-200A - Small Cell Lung Cancer
  • NovoTTF-200A - Small Cell Lung Cancer Product Overview
  • Optune - Brain Metastasis
  • Optune - Brain Metastasis Product Overview
  • Optune - Brain Metastasis Clinical Trial
  • Optune - Breast Cancer
  • Optune - Breast Cancer Product Overview
  • Optune - Cervical Cancer
  • Optune - Cervical Cancer Product Overview
  • Optune - Colorectal Carcinoma
  • Optune - Colorectal Carcinoma Product Overview
  • Optune - Ependymoma
  • Optune - Ependymoma Product Overview
  • Optune - Gastric Adenocarcinoma
  • Optune - Gastric Adenocarcinoma Product Overview
  • Optune - Gastric Adenocarcinoma Clinical Trial
  • Optune - Gliosarcoma
  • Optune - Gliosarcoma Product Overview
  • Optune - Liver Cancer
  • Optune - Liver Cancer Product Overview
  • Optune - Malignant Melanoma
  • Optune - Malignant Melanoma Product Overview
  • Optune - Medulloblastoma
  • Optune - Medulloblastoma Product Overview
  • Optune - Meningioma
  • Optune - Meningioma Product Overview
  • Optune - Mesothelioma
  • Optune - Mesothelioma Product Overview
  • Optune - Non - Small Cell Lung Cancer
  • Optune - Non - Small Cell Lung Cancer Product Overview
  • Optune - Non - Small Cell Lung Cancer Clinical Trial
  • Optune - Ovarian Cancer
  • Optune - Ovarian Cancer Product Overview
  • Optune - Ovarian Cancer Clinical Trial
  • Optune - Pancreatic Cancer
  • Optune - Pancreatic Cancer Product Overview
  • Optune - Pancreatic Cancer Clinical Trial
  • Optune - Pediatric Glioma
  • Optune - Pediatric Glioma Product Overview
  • Optune - Pediatric Glioma Clinical Trial
  • Optune - Renal Adenocarcinoma
  • Optune - Renal Adenocarcinoma Product Overview
  • Optune - Small Cell Lung Cancer
  • Optune - Small Cell Lung Cancer Product Overview
  • Optune - Urinary Transitional Cell Carcinoma
  • Optune - Urinary Transitional Cell Carcinoma Product Overview
  • Optune Plus Bevacizumab - Recurrent Glioblastoma
  • Optune Plus Bevacizumab - Recurrent Glioblastoma Product Overview
  • Optune Plus Bevacizumab - Recurrent Glioblastoma Clinical Trial
  • Optune With Marizomib and Temozolomide - Glioblastoma
  • Optune With Marizomib and Temozolomide - Glioblastoma Product Overview
  • Optune With Marizomib and Temozolomide - Glioblastoma Clinical Trial
NovoCure Ltd - Key Competitors

NovoCure Ltd - Key Employees
  • NovoCure Ltd - Key Employee Biographies
NovoCure Ltd - Locations and Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Recent Developments
  • NovoCure Ltd, Recent Developments
  • Nov 10, 2020: Novocure announces agenda for Virtual Research and Development Day
  • Oct 29, 2020: Novocure announces strategic alliance with NYU Grossman School of Medicine for preclinical and clinical Research
  • Jul 28, 2020: Novocure announces recipients of 2nd Annual AACR-Novocure grants for tumor treating fields research program
  • Mar 12, 2020: Preclinical data show tumor treating fields induces immunogenic cell death resulting in enhanced antitumor efficacy when combined with Anti-PD-1 therapy
  • Feb 27, 2020: Novocure reports fourth quarter and full year 2019 financial results and provides company update
  • Feb 11, 2020: Mesothelioma treatment center offers new at-home device
  • Jan 21, 2020: Novocure announces national reimbursement in Israel for Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma
  • Jan 13, 2020: Novocure announces fourth quarter and full year 2019 preliminary net revenues and provides company update
  • Jan 09, 2020: Zai Lab and Novocure announce first patient enrolled in a phase 2 pilot trial of tumor treating fields together with chemotherapy as first-line treatment of gastric cancer
  • Oct 31, 2019: Novocure reports third quarter 2019 financial results and provides company update
Appendix
  • Methodology
  • About the Publisher
  • Contact Us
  • Disclaimer
List of Tables
  • NovoCure Ltd Pipeline Products and Ongoing Clinical Trials Overview
  • NovoCure Ltd Pipeline Products by Equipment Type
  • NovoCure Ltd Pipeline Products by Indication
  • NovoCure Ltd Ongoing Clinical Trials by Trial Status
  • NovoCure Ltd, Key Facts
  • NovoCure Ltd, Major Products and Services
  • NovoCure Ltd Number of Pipeline Products by Development Stage
  • NovoCure Ltd Pipeline Products Summary by Development Stage
  • NovoCure Ltd Ongoing Clinical Trials by Trial Status
  • NovoCure Ltd Ongoing Clinical Trials Summary
  • MAXPOINT Treatment Planning Software - Product Status
  • MAXPOINT Treatment Planning Software - Product Description
  • NovoTTF-200A - Small Cell Lung Cancer - Product Status
  • NovoTTF-200A - Small Cell Lung Cancer - Product Description
  • Optune - Brain Metastasis - Product Status
  • Optune - Brain Metastasis - Product Description
  • Optune - Brain Metastasis - A Phase II Randomized Study of TTField Therapy (150 kHz) Versus Supportive Care in Non-small Cell Lung Cancer Patients with 1-5 Brain Metastases Following Optimal Standard Local Treatment
  • Optune - Brain Metastasis - Phase II Study of Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma with Brain Metastasis
  • Optune - Brain Metastasis - Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma
  • Optune - Brain Metastasis - Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer
  • Optune - Breast Cancer - Product Status
  • Optune - Breast Cancer - Product Description
  • Optune - Cervical Cancer - Product Status
  • Optune - Cervical Cancer - Product Description
  • Optune - Colorectal Carcinoma - Product Status
  • Optune - Colorectal Carcinoma - Product Description
  • Optune - Ependymoma - Product Status
  • Optune - Ependymoma - Product Description
  • Optune - Gastric Adenocarcinoma - Product Status
  • Optune - Gastric Adenocarcinoma - Product Description
  • Optune - Gastric Adenocarcinoma - A Phase II Pilot Study of Tumor Treating Fields Together with Chemotherapy as First-line Treatment of Gastric Cancer
  • Optune - Gliosarcoma - Product Status
  • Optune - Gliosarcoma - Product Description
  • Optune - Liver Cancer - Product Status
  • Optune - Liver Cancer - Product Description
  • Optune - Malignant Melanoma - Product Status
  • Optune - Malignant Melanoma - Product Description
  • Optune - Medulloblastoma - Product Status
  • Optune - Medulloblastoma - Product Description
  • Optune - Meningioma - Product Status
  • Optune - Meningioma - Product Description
  • Optune - Mesothelioma - Product Status
  • Optune - Mesothelioma - Product Description
  • Optune - Non - Small Cell Lung Cancer - Product Status
  • Optune - Non - Small Cell Lung Cancer - Product Description
  • Optune - Non - Small Cell Lung Cancer - Prophylactic Tumor Treating Fields in Management of Patients with Small Cell Lung Cancer
  • Optune - Non - Small Cell Lung Cancer - Study Evaluating the Safety and Efficacy of Tumor Treating Fields Together with KEYTRUDA (pembrolizumab) in Subjects with Non-small Cell Lung Cancer
  • Optune - Ovarian Cancer - Product Status
  • Optune - Ovarian Cancer - Product Description
  • Optune - Ovarian Cancer - An Open Label Pilot Study of the NovoTTF-100L(O) System (NovoTTF Therapy) (200 kHz) Concomitant with Weekly Paclitaxel for Recurrent Ovarian Carcinoma
  • Optune - Ovarian Cancer - Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 200kHz) Concomitant with Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer: ENGOT-ov50 / GOG-3029 / INNOVATE-3
  • Optune - Pancreatic Cancer - Product Status
  • Optune - Pancreatic Cancer - Product Description
  • Optune - Pancreatic Cancer - Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
  • Optune - Pediatric Glioma - Product Status
  • Optune - Pediatric Glioma - Product Description
  • Optune - Pediatric Glioma - A Phase I Trial of the Optune NovoTTF-200A System with Concomitant Temozolomide and Bevacizumab in Pediatric Patients with High-grade Glioma (HUMC 1612)
  • Optune - Pediatric Glioma - Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-grade Glioma and Ependymoma
  • Optune - Renal Adenocarcinoma - Product Status
  • Optune - Renal Adenocarcinoma - Product Description
  • Optune - Small Cell Lung Cancer - Product Status
  • Optune - Small Cell Lung Cancer - Product Description
  • Optune - Urinary Transitional Cell Carcinoma - Product Status
  • Optune - Urinary Transitional Cell Carcinoma - Product Description
  • Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Status
  • Optune Plus Bevacizumab - Recurrent Glioblastoma - Product Description
  • Optune Plus Bevacizumab - Recurrent Glioblastoma - A Phase II Trial of Tumor Treating Fields (TTfields) Concomitant with Radiosurgery for the Treatment of Recurrent, Bevacizumab-naïve Glioblastoma
  • Optune With Marizomib and Temozolomide - Glioblastoma - Product Status
  • Optune With Marizomib and Temozolomide - Glioblastoma - Product Description
  • Optune With Marizomib and Temozolomide - Glioblastoma - Phase 1B, Multicenter, Open-label Study of Marizomib Combined with Temozolomide and Radiotherapy in Patients with Newly Diagnosed who Grade IV Malignant Glioma
  • NovoCure Ltd, Key Employees
  • NovoCure Ltd, Key Employee Biographies
  • NovoCure Ltd, Subsidiaries
  • Glossary
List of Figures
  • NovoCure Ltd Pipeline Products by Equipment Type
  • NovoCure Ltd Pipeline Products by Development Stage
  • NovoCure Ltd Ongoing Clinical Trials by Trial Status
Note: Product cover images may vary from those shown
3 of 3
  • SonALASense Inc
  • Monteris Medical Inc
  • MDxHealth SA
  • MagForce AG
  • Hologic Inc
  • Flowonix Medical Inc
  • Advanz Pharma Corp Ltd
Note: Product cover images may vary from those shown
Adroll
adroll